CytRx's Tamibarotene Receives Positive Opinion From The Committee For Orphan Medicinal Products In The European Union For Treatment Of APL
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register. This favorable opinion for tamibarotene in the European Union (EU) is in addition to the Orphan Drug Designation for APL and Fast Track Designation for the treatment of adult patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide granted by the U.S. Food and Drug Administration (FDA) in October 2007.
Sexual Health